Skip to content
Open access

Bleomycin-Associated Pulmonary Toxicity in Adult Cancer Patients: Clinical Characteristics and Outcomes from a Single-Center Retrospective Cohort

Oct 2026 · International Journal of Cancer Management · Vol 19 · 0 citations · 15 references

TL;DR

Bleomycin-associated pulmonary toxicity was documented in nearly one-quarter of adult patients with cancer receiving bleomycin, whereas pulmonary fibrosis was uncommon, highlighting the clinical impact of bleomycin-associated pulmonary toxicity.

Abstract

Background: Bleomycin remains an important component of curative-intent chemotherapy regimens for several malignancies, particularly Hodgkin lymphoma and germ cell tumors. However, bleomycin-associated pulmonary toxicity is a clinically important adverse effect that may lead to treatment interruption, hospitalization, respiratory failure, or irreversible pulmonary fibrosis. Real-world data from Middle Eastern oncology populations remain limited. Objectives: This study aimed to determine the frequency, clinical characteristics, and outcomes of bleomycin-associated pulmonary toxicity among adult patients with cancer treated at a tertiary care center. Methods: This single-center retrospective cohort study was conducted at King Abdullah Medical City, Makkah, Saudi Arabia. Adult patients with cancer who received at least one dose of bleomycin between January 2019 and June 2026 were identified through electronic health records and screened for eligibility. Data on demographic characteristics, cancer diagnosis, bleomycin indication and cumulative dose, pulmonary assessments, imaging findings, pulmonary function testing, toxicity grading, and clinical outcomes were extracted. The primary outcome was the proportion of patients with documented bleomycin-associated pulmonary toxicity during the available follow-up period. Secondary outcomes included pulmonary fibrosis, toxicity severity, oxygen requirement, mechanical ventilation, hospitalization, treatment modification or discontinuation, and recovery. Results: Among 117 patients, documented bleomycin-associated pulmonary toxicity occurred in 27 patients (23.1%; 95% confidence interval [CI], 15.8% - 31.8%), and pulmonary fibrosis occurred in 4 patients (3.4%; 95% CI, 0.9% - 8.5%). Post-bleomycin pulmonary function testing was documented in only 3 patients. Pulmonary toxicity was frequently accompanied by hospitalization, an oxygen requirement, and treatment modification. Recorded oxygen exposure was associated with pulmonary toxicity in an exploratory unadjusted analysis; however, its timing relative to toxicity onset was uncertain. The small number of events and incomplete documentation precluded reliable adjusted risk factor assessment. Conclusions: Bleomycin-associated pulmonary toxicity was documented in nearly one-quarter of adult patients with cancer receiving bleomycin, whereas pulmonary fibrosis was uncommon. These findings highlight the clinical impact of bleomycin-associated pulmonary toxicity and the need for standardized baseline and follow-up pulmonary assessments, particularly because post-treatment pulmonary function testing was rarely documented.

Read PDF

Similar papers

Open access Sep 2026

First-line systemic treatment patterns and outcomes in lung cancer patients with malignant pleural effusion: a retrospective multicenter study

Background Malignant pleural effusion (MPE) is a frequent complication of advanced lung cancer with poor prognosis. The optimal first-line systemic treatment for these patients remains unclear. This study aimed to evaluate first-line systemic treatment patterns and outcomes in lung cancer patients with MPE. Methods Thi...

Yuan-Yuan Zhang, Ran Wang, Yi Xiang et al. · 0 citations
Review Open access Oct 2026

Real-world outcomes and immune-related adverse events in Canadian patients with non-small cell lung cancer receiving neoadjuvant platinum-based chemotherapy and nivolumab.

710 Background: Lung cancer is the leading cause of cancer-related mortality in Canada. Patients with resectable non-small cell lung cancer (NSCLC) can receive curative intent surgery, though relapse rates are high. The addition of nivolumab to neoadjuvant platinum-doublet chemotherapy has recently become the s...

Daniel Wang, S. Moore · 0 citations
Open access Sep 2026

Real-world clinical outcomes and safety of anlotinib-containing regimens in pediatric solid tumors: a retrospective cohort study at a Chinese center

Background and aim This retrospective cohort study aimed to characterize the real-world clinical outcomes and treatment-emergent adverse events (TEAEs) of anlotinib-containing regimens among pediatric patients with solid tumors treated at the Children’s Hospital of Zhejiang University School of Medicine from January 20...

Qiao Hua, Zhou Xia, Ya-Qing Gu et al. · 0 citations
Open access Sep 2026

Platinum-Based Chemotherapy Regimens and the Incidence of Chemotherapy Toxicity in Patients with Lung Cancer in Medan, Indonesia

Introduction: Platinum-based chemotherapy remains the standard first-line therapy for advanced lung cancer; however, its administration is frequently associated with various hematologic and non-hematologic toxicities that may affect patient outcomes and quality of life. Understanding the toxicity profile of platinum-ba...

Faidul Hidayati Siska Ginting, N. Soeroso, S. Tarigan et al. · 0 citations
Open access Oct 2026

Utility (or futility) of inpatient chemotherapy in patients with advanced solid organ cancers near end of life (FOCUS-EOL).

289 Background: Chemotherapy near the end of life carries limited clinical benefit. We evaluated outcomes of patients with solid organ malignancies who received inpatient cytotoxic chemotherapy at a tertiary cancer center. Methods: We performed a retrospective study of adults with solid organ malignancies who...

Adeel Arshad, P. Bhateja, Alyssa Antonini et al. · 0 citations
Oct 2026

Systemic anticancer therapy for refractory malignant bowel obstruction in advanced cancer patients: a retrospective cohort study.

OBJECTIVES Malignant bowel obstruction (MBO) is a common but severe complication of advanced cancer. The role of systemic anticancer therapy in patients with inoperable MBO remains poorly defined. This study aimed to assess the efficacy of systemic anticancer therapy in this setting. METHODS We conducted a retrospect...

Emmanuel Ferber, M. Benderra, Joseph Gligorov et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.